<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735499</url>
  </required_header>
  <id_info>
    <org_study_id>Botox instillation study</org_study_id>
    <nct_id>NCT02735499</nct_id>
  </id_info>
  <brief_title>Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB)</brief_title>
  <official_title>Bladder Instillation of Botox With EMDA for OAB - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital of Vestfold</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Instillation treatment with onabotulinumtoxin A (BOTOX®) in the urinary bladder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot study to evaluate the effect of instillation treatment with onabotulinumtoxin A
      (BOTOX®) in the urinary bladder using Electromotive Drug Application (EMDA) in women with
      overactive bladder.

      15 women with therapy-resistant OAB will be included. All patients must be qualified for
      conventional cystoscopic Botox injection. The study is not randomized or blinded. Follow-up
      time is six months with voiding charts and three questionnaires (Urinary Distress Inventory-6
      (UDI-6), Incontinence Impact Questionnaire-7 (IIQ-7), International Consultation on
      Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) as well as a
      satisfaction with treatment Visual analog scale (VAS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of leakage episodes</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured with a 24-hour voiding chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in grams leakage</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured with a 24-hour voiding chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of voids</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured with a 24-hour voiding chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean voided volume</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured with a 24-hour voiding chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Distress Inventory-6 score (UDI-6)</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Incontinence Impact Questionnaire-7 score (IIQ-7)</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Consultation on Incontinence Questionnaire-Short Form score (ICIQ-SF)</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in flow rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measured by flowmetry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Treatment with Botox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Onabotulinum toxin A. 200 units of Botox installed into the bladder by catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onabotulinum toxin A</intervention_name>
    <description>Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes</description>
    <arm_group_label>Treatment with Botox</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent form signed

          -  OAB/urgency incontinence of at least 3 months duration

          -  Conservative treatment (medicines, electrical stimulation) has been tried without
             sufficient benefit

          -  There is indication for cystoscopic injection treatment with Botox®

          -  More than 3 months since any previous treatment with Botox®

          -  Detrusor overactivity documented by cystometry is desirable, but not obligatory

        Exclusion Criteria:

          -  Age below 18 years

          -  Mixed incontinence with predominant stress component

          -  Insufficient understanding of Norwegian and / or unable to fill out the necessary
             forms

          -  Ongoing urinary tract infection (UTI) (defined as positive urine stix (nitrite and
             leucocytes) with symptoms of UTI) must be treated before inclusion.

          -  Any contraindication stated in the Summary of product characteristics (SPC) for Botox
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hjalmar A Schiotz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vestfold Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Ob/Gyn, The Hospital of Vestfold</name>
      <address>
        <city>Tonsberg</city>
        <zip>N-3103</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.20431/2456-0561.0202002</url>
    <description>Final article</description>
  </link>
  <reference>
    <citation>Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3. Review.</citation>
    <PMID>22161392</PMID>
  </reference>
  <reference>
    <citation>Kajbafzadeh AM, Ahmadi H, Montaser-Kouhsari L, Sharifi-Rad L, Nejat F, Bazargan-Hejazi S. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application. Urology. 2011 Feb;77(2):439-45. doi: 10.1016/j.urology.2010.06.003. Epub 2010 Aug 30.</citation>
    <PMID>20800886</PMID>
  </reference>
  <results_reference>
    <citation>Schiøtz HA, Mai HT, Zabielska R. Intravesical Electromotive Botulinum Toxin in Women with Overactive Bladder - a pilot study. AJGO 2017; 2: 4-10. https://www.arcjournals.org/pdfs/ajgo/v2-i2/2.pdf</citation>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital of Vestfold</investigator_affiliation>
    <investigator_full_name>Dr Hjalmar A Schiotz, MD, PhD</investigator_full_name>
    <investigator_title>Senior consultant gynecologist</investigator_title>
  </responsible_party>
  <keyword>onabotulinum toxin A</keyword>
  <keyword>Urinary bladder</keyword>
  <keyword>EMDA</keyword>
  <keyword>iontophoresis</keyword>
  <keyword>electrophoresis</keyword>
  <keyword>Urinary incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

